You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Also known as: Abdominal Pain (AP) / Abdominal Pains / Abdominal Pain / [D]Abdominal pain NOS / Gut pain / Pain abdo / Abdo pain / Abd. pain / Pain abdominal / Abdominal pain NOS / Unspecified abdominal pain
DrugDrug NameDrug Description
DB09054IdelalisibIdelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
DrugDrug NamePhaseStatusCount
DB09020Bisacodyl2Completed1
DB00297Bupivacaine2Recruiting1
DB00829Diazepam2Completed1
DB00470Dronabinol2Completed3
DB00620Triamcinolone2Recruiting1
DB00215Citalopram2 / 3Recruiting1
DB00104Octreotide2 / 3Completed1
DB00316Acetaminophen3Recruiting1
DB00207Azithromycin3Completed1
DB01151Desipramine3Completed1
DB06211Doripenem3Terminated1
DB00668Epinephrine3Completed1
DB00465Ketorolac3Recruiting1
DB00281Lidocaine3Completed1
DB00760Meropenem3Terminated1
DB00296Ropivacaine3Recruiting1
DB09372Tannic acid3Completed1
DB00193Tramadol3Recruiting1
DB01234Dexamethasone4Recruiting1
DB01175Escitalopram4Recruiting1
DB00736Esomeprazole4Completed1
DB00295Morphine4Completed1
DB00904Ondansetron4Recruiting1
DB00230Pregabalin4Terminated1
DB00234Reboxetine4Recruiting1
DB09153Sodium Chloride4Recruiting1
DB00518AlbendazoleNot AvailableCompleted1
DB00518AlbendazoleNot AvailableRecruiting1
DB00668EpinephrineNot AvailableRecruiting1
DB00602IvermectinNot AvailableCompleted1
DB00581LactuloseNot AvailableNot Yet Recruiting1
DB00281LidocaineNot AvailableRecruiting1
DB00295MorphineNot AvailableActive Not Recruiting1
DB00911TinidazoleNot AvailableRecruiting1